Purpose: COX-2 is known to be elevated in breast cancer, but the clinical relevance is still a matter of debate. The purpose of this study was to determine the prognostic significance and relationship of COX-2 to hormone receptors. Methods: Between January 2005 and February 2007, 80 specimens from breast cancer patients at Korea University Anam Hospital were reviewed by one pathologist. COX-2 was analyzed as overexpressed if ＞10% of the cells were stained. Clinical characteristics, hormone receptor status, and other prognostic factors were investigated to determine their association with COX-2 expression. Results: COX-2 was overexpressed in 12 patients (15%). Two patients had locoregional recurrence, eight patients had systemic metastasis, and one patient died. There was no statistically significant correlation between COX-2 expression and age, size, nodal status, histological grade, hormone receptor status, and HER-2/neu positivity. Among tumors that had a positive expression of ER and PR, COX-2 expression was related to larger size (P-value 0.001 and 0.009, respectively) and nodal status (P-value 0.048 and 0.009, respectively). However, there was no statistically significant correlation with tumors that had negative ER or PR expression. Conclusion: This study suggests that in breast cancer, COX-2 expression has no relationship with clinicopathologic factors; however, a correlation was noted in size and nodal status for ER-and PR-positive tumors. Further prospective study with larger population to clarify the relationship between COX-2 expression and hormone receptor status is necessary. (J Korean Surg Soc 2010;78:140-148)
INTRODUCTION
Estrogen is an important factor in the etiology of breast cancer. It is regulated by the cytochrome P-450 enzyme complex known as aromatase, which catalyzes androgen to produce estrogen. Cyclooxygenase-2 (COX-2) plays a role in the regulation of estrogen since it produces prostaglandin E2, which increases the expression of the cytochrome P-450 enzyme complex. Prostaglandin E2 is produced not only by COX-2, but by COX-1. However, COX-1 is constitutively produced by most tissues, while COX-2 is induced in the environment with mitogens, cytokines, hormones, and serum. Molecular studies suggest that COX-2 is related to mutagenesis, angiogenesis, inhibition of apoptosis, and aromatase-catalyzed estrogen biosynthesis; there is also a hypothesis that local estrogen levels induced by elevated aromatase activity stimulate tumor growth, thus the development and role of COX-2 seems to be essential in breast cancer. (1) (2) (3) (4) (5) COX-2 is known to be expressed in several cancers, including colorectal, prostate, lung, pancreas, and breast.
(6-11) Moreover, many studies suggest that COX-2 is a prognostic factor for various cancers, especially colorectal 2) Immunohistochemistry
Archived paraffin-embedded tissue samples were studied.
Two consecutive 4μm-thick sections were cut from the paraffin-embedded block. One section from the specimen was routinely stained with hematoxylin-and-eosin. Another section was immunohistochemically stained for COX-2.
Tissue sections were deparaffinized in xylene, and rehydrated with a graded series of ethanol to water. The activity of peroxidase was inhibited by precipitation in 
Assessment of ER and progesterone receptor (PR) status
was done by standard immunohistochemical methods and considered positive if the value was ＞10% of nuclear staining. Evaluation was done by single pathologist using a light microscope.
3) Statistical analysis
Comparison of clinicopathologic factors between COX-2 overexpressed and unexpressed patients were assessed using SPSS, version 12. Chi-square tests were used for univariate analysis, and logistic regression with forward procedure was used for statistically significant factors in multivariate analysis. For comparison of disease-free survival, KaplanMeier survival curves were used. Statistical significance was regarded when the P-value was ＜0.05.
RESULTS
The correlation between clinicopathologic factors and COX-2 expression of 80 patients are summarized in Table   2 . There were 12 patients with overexpressed COX-2 and 68 patients with unexpressed COX-2, with a positivity rate of 15%.
No statistical significance was found between COX-2 overexpressed patients and COX-2 unexpressed patients with respect to age, tumor size, nodal status, and hormone receptors status.
The mean follow-up period was 34.125±8.266 months.
Eight patients developed distant metastasis (two patients in the liver and bone, three patients in bone only, two patients in the lungs, and one patient in the brain). One patient had breast recurrence and one patient died.
We divided the group into ER-positive and -negative groups to compare the differences in clinicopathologic factors between COX-2-overexpressed and -unexpressed patients in each group. Comparison of the ER and PR group is outlined in Table 3 and 4. COX-2 overexpression was more common in larger tumors and higher nodal status with P-values of ＜0.001 and 0.048, respectively.
Larger size and higher nodal status was more commonly positive for COX-2 overexpression patients in the PRpositive group (Table 4) with a P-value of 0.009. However in multivariate analysis, no correlation was found between clinicopathologic parameters and COX-2 expression. There were no statistically significant factors in the ER-negative group and PR-negative group.
There were no differences in disease-free survival according to COX-2 positivity with a P-value of 0.424 (Fig.   2 ). Disease-free survival was compared according to ER and PR status, but statistical significance was not found (Fig. 3) . This study was conducted to determine the significance of COX-2 in breast cancer, but we found no association between clinicopathologic factors, including age, tumor size, nodal status, histological grade, hormone receptor surgery. The preliminary report shows overall response rate was 58.6% for combination therapy, 54.5% for exemestane alone group and 62% for letrozole alone group. They suggested that COX-2 inhibitor contribution is yet to be determined since they are still in initial phase of study. (24) Falandry et al. (23) there is yet no agreement concerning the definition of COX-2 positivity and we think this might be a priority matter internationally.
DISCUSSION
In conclusion, we identified no correlation between clinicopathologic factors and COX-2 expression, but size and nodal status appear to be related to COX-2 positivity in the ER-positive group and controversies still remain for the clinical significance of COX-2 expression.
